Status:

COMPLETED

Soluble CD95 Ligand Role in the Pathophysiology of Non-infectious Active Uveitis

Lead Sponsor:

University Hospital, Bordeaux

Conditions:

Non-Infectious Active Uveitis

Eligibility:

All Genders

18+ years

Brief Summary

The study aims at defining the role of soluble CD95 Ligand in the physiopathology of the non-infectious uveitis. Soluble CD95 Ligand might have a prognostic interest as well as potential for the disco...

Detailed Description

Non-Infectious active uveitis is a severe inflammatory ocular disease which can expose to the blindness. Actually, the knowledge of the physiopathology of uveitis stay poorly. CD95 Ligand (CD95-L) bel...

Eligibility Criteria

Inclusion

  • Diagnosis of non-infectious uveitis according to the SUN (Standardization of the Uveitis Nomenclature) working Group;
  • Age ≥ 18 years;
  • being affiliated to health insurance,
  • willing to participate.

Exclusion

  • Pregnant or breastfeeding women,
  • patient under legal protection measure ,
  • poor understanding of the French language

Key Trial Info

Start Date :

November 17 2020

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

March 10 2023

Estimated Enrollment :

20 Patients enrolled

Trial Details

Trial ID

NCT04354909

Start Date

November 17 2020

End Date

March 10 2023

Last Update

May 16 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

CHU Bordeaux

Bordeaux, France